IVERIC bio, Inc. (ISEE)
Stock Price:
$4.40 USD
-0.14 (-2.98%)
Updated Aug 11, 2020 4:00 PM EDT - Market closed
After-hours: $4.54 +0.15 (3.30%) Aug 11, 5:14 PM
Key Info
| Market Cap |
225.62M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-65.58M |
| Shares Out |
88.49M |
| EPS (ttm) |
-1.33 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 11, 2020 |
| Last Price |
$4.40 |
| Previous Close |
$4.53 |
| Change ($) |
-0.14 |
| Change (%) |
-2.98% |
| Day's Open |
4.66 |
| Day's Range |
4.36 - 4.66 |
| Day's Volume |
378,800 |
| 52-Week Range |
0.91 - 8.97 |
More Stats
| Market Cap |
225.62M |
| Enterprise Value |
n/a |
| Earnings Date (est) |
Nov 4, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
88.49M |
| Float |
71.17M |
| EPS (basic) |
-1.34 |
| EPS (diluted) |
-1.33 |
| FCF / Share |
-0.95 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
2.30M |
| Short Ratio |
1.07 |
| Short % of Float |
3.19% |
| Beta |
2.04 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
1.60 |
| Revenue |
n/a |
| Operating Income |
-70.66M |
| Net Income |
-65.58M |
| Free Cash Flow |
-54.26M |
| Net Cash |
245.59M |
| Net Cash / Share |
4.78 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-24.29% |
| ROE |
-38.60% |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (2)
| Buy |
2 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$13.00*
(195.79% upside)
Low
11.0
Current: $4.40
High
15.0
Target: 13.00
*Average 12-month price target from 2 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|
| Revenue | - | - | 210 | 50.91 | 51.51 | 41.26 | - | - | - |
| Revenue Growth | - | - | 312.46% | -1.16% | 24.83% | - | - | - | - |
| Gross Profit | - | - | 210 | 50.91 | 51.51 | 41.26 | - | - | - |
| Operating Income | -61.27 | -65.35 | 108 | -196 | -124 | -80.51 | -47.43 | -13.68 | -19.63 |
| Net Income | -58.86 | 63.09 | 114 | -193 | -106 | -117 | -51.15 | -14.56 | -18.63 |
| Shares Outstanding | 42.22 | 37.06 | 35.92 | 35.49 | 34.58 | 33.26 | 9.00 | 1.45 | 1.39 |
| Earnings Per Share | -1.39 | 1.70 | 3.17 | -5.45 | -3.06 | -3.51 | -6.34 | -14.89 | -18.27 |
| EPS Growth | - | -46.37% | - | - | - | - | - | - | - |
| Operating Cash Flow | -48.49 | -41.91 | -122 | -109 | -78.53 | 111 | -48.78 | -13.10 | -19.12 |
| Capital Expenditures | 0.15 | - | - | -0.57 | -2.61 | -1.66 | -0.01 | - | - |
| Free Cash Flow | -48.34 | -41.91 | -122 | -109 | -81.14 | 109 | -48.78 | -13.10 | -19.13 |
| Cash & Equivalents | 126 | 131 | 167 | 289 | 297 | 464 | 211 | 4.30 | 6.40 |
| Total Debt | 0.50 | - | - | - | - | - | - | 11.04 | - |
| Net Cash / Debt | 125 | 131 | 167 | 289 | 297 | 464 | 211 | -6.74 | 6.40 |
| Assets | 130 | 137 | 176 | 300 | 429 | 480 | 218 | 4.88 | 7.73 |
| Liabilities | 12.98 | 13.21 | 138 | 394 | 369 | 351 | 47.96 | 14.41 | 110 |
| Book Value | 117 | 124 | 38.04 | -94.62 | 59.95 | 129 | 170 | -123 | -102 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
IVERIC bio, Inc. |
| Country |
United States |
| Employees |
47 |
| CEO |
Glenn P. Sblendorio |
Stock Information
| Ticker Symbol |
ISEE |
| Stock Exchange |
NASDAQ |
| Sector |
Services |
| Industry |
Specialty Retail, Other |
| Unique Identifier |
NASDAQ: ISEE |
Description
IVERIC bio, Inc., a biopharmaceutical company, develops novel therapies to treat ophthalmic diseases with a focus on age-related and orphan retinal diseases. The company is developing Zimura, an inhibitor of complement factor C5, which is in Phase IIb clinical trials for the treatment of geographic atrophy (GA), a late-stage form of dry age-related macular degeneration (AMD) characterized by retinal cell death and degeneration of tissue in the central portion of the retina known as the macula; and autosomal recessive Stargardt disease (STGD1), which is an orphan inherited retinal disease (IRD). It is also developing High temperature requirement A serine peptidase 1 protein (HtrA1) inhibitors for the treatment of GA secondary to dry AMD and other age-related retinal diseases, such as wet AMD and idiopathic polypoidal choroidal vasculopathy. The company has a license agreement with the University of Florida Research Foundation (UFRF) and the University of Pennsylvania for the development and commercialization of novel adeno-associated virus (AAV) gene therapy product candidate for the treatment of rhodopsin-mediated autosomal dominant retinitis pigmentosa (RHO-adRP); and Best disease and other bestrophinopathies. It also has a research agreement with the University of Massachusetts Medical School to utilize the minigene therapy approach to create AAV gene therapy product candidates targeting Leber Congenital Amaurosis type 10 and STGD1; and to evaluate various AAV gene delivery methods for potential application in the eye. The company was formerly known as Ophthotech Corporation and changed its name to IVERIC bio, Inc. in April 2019. IVERIC bio, Inc. was founded in 2007 and is headquartered in New York, New York.